中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(1): 84-88

Association of tuberous sclerosis gene 1/2 mutations with the progression of hepatocellular carcinoma and prognosis

DOI: 10.3969/j.issn.1001-5256.2021.01.017

  • Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 225500, China

  • Received Date: 2020-07-02
  • Accepted Date: 2020-08-03
  • Published Date: 2021-01-20
    Abstract
  •   Objective  To investigate the association of tuberous sclerosis gene 1/2 (TSC1/2) mutation with disease severity and prognosis in patients with hepatocellular carcinoma (HCC), and to provide a feasible basis for the diagnosis and treatment of HCC.  Methods  A total of 492 patients with HCC who were admitted to The Affiliated Hospital of Jiangsu University from January 2012 to January 2020 were enrolled, among whom 59 had TSC1/2 mutations (20 with TSC1 mutations, 41 with TSC2 mutations, and 2 had both TSC1 and TSC2 mutations). The clinical features of patients with TSC1/2 mutations were analyzed, and the association of TSC1/2 mutations with the clinical stage of HCC was analyzed. The 35 patients in the mutation group and 35 in the non-mutation group were followed up for 3 years to observe the effect of TSC1/2 mutations on the prognosis of HCC. The chi-square test was used for comparison of categorical data between groups; the Kruskal-Wallis H test was used for comparison of ranked data between groups; a multivariate logistic regression analysis was used to investigate association; the Kaplan-Meier survival analysis was used to analyze follow-up data.  Results  For the 492 patients with HCC, the overall TSC1/2 mutation rate was 11.99%. There were no significant differences in sex, age, Child score, and tumor size between the TSC1/TSC2 mutation group and the non-mutation group (all P > 0.05), while there were significant differences in tumor number, extrahepatic metastasis, and PS score between the two groups (all P < 0.05). The logistic regression analysis showed that TSC1/TSC2 gene mutation was positively correlated with the severity of HCC (odds ratio=1.706, P < 0.05). The follow-up results showed that the TSC1/2 mutation group had a significantly lower survival rate than the non-mutation group, and there was a significant difference in 3-year mortality rate between the TSC1/2 mutation group and the non-mutation group (60.3% vs 38.6%, χ2=3.923, P < 0.05).  Conclusion  TSC1/TSC2 gene mutation may predict the malignant progression of HCC in the early stage, and patients with TSC1/2 mutation tend to have poor prognosis. Targeted drug therapy for gene mutations may have a certain effect in delaying the progression of HCC.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    BUDNY A, KOZŁOWSKI P, KAMIN'SKA M, et al. Epidemiology and risk factors of hepatocellular carcinoma[J]. Pol Merkur Lekarski, 2017, 43(255): 133-139.
    [2]
    ZHU AX, WALLNER KE, FRIVOLD GP, et al. Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction[J]. Brachytherapy, 2006, 5(4): 262-265. DOI: 10.1016/j.brachy.2006.08.004
    [3]
    CROCETTI L, BARGELLINI I, CIONI R. Loco-regional treatment of HCC: Current status[J]. Clin Radiol, 2017, 72(8): 626-635. DOI: 10.1016/j.crad.2017.01.013
    [4]
    ALGHAMDI MA, LEE YR, SWIHA M, et al. The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 2017, 9(14): 4918-4928.
    [5]
    KAPLAN DE, YU S, TADDEI TH, et al. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost[J]. J Clin Oncol, 2017, 35: 385.
    [6]
    CLARK JW, EDER JP, RYAN D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors[J]. Clin Cancer Res, 2005, 11(15): 5472-5480. DOI: 10.1158/1078-0432.CCR-04-2658
    [7]
    STRUMBERG D, AWADA A, HIRTE H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?[J]. Eur J Cancer, 2006, 42(4): 548-556. DOI: 10.1016/j.ejca.2005.11.014
    [8]
    ZUCMAN-ROSSI J, VILLANUEVA A, NAULT JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239.e4. DOI: 10.1053/j.gastro.2015.05.061
    [9]
    JOZWIAK J, JOZWIAK S, WLODARSKI P. Possible mechanisms of disease development in tuberous sclerosis[J]. Lancet Oncol, 2008, 9(1): 73-79. DOI: 10.1016/S1470-2045(07)70411-4
    [10]
    NORTHRUP H, KRUEGER DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference[J]. Pediatr Neurol, 2013, 49(4): 243-254. DOI: 10.1016/j.pediatrneurol.2013.08.001
    [11]
    LI SQ, LI HZ, ZHANG YS. Clinical analysis of spontaneous rupture in tuberous sclerosis-related renal angiomyolipoma[J]. J Clin Urol, 2014, 29(12): 1070-1072. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201412010.htm

    李书强, 李汉忠, 张玉石. 结节性硬化症相关肾错构瘤自发性破裂出血临床诊治分析[J]. 临床泌尿外科杂志, 2014, 29(12): 1070-1072. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW201412010.htm
    [12]
    XU B, ZHANG Q, JIN J. Laparoscopic aspiration for central renal angiomyolipoma: A novel technique based on single-center initial experience[J]. Urology, 2013, 81(2): 313-318. DOI: 10.1016/j.urology.2012.09.047
    [13]
    HO DWH, CHAN LK, CHIU YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication[J]. Gut, 2017, 66(8): 1496-1506. DOI: 10.1136/gutjnl-2016-312734
    [14]
    Chinese Society of Clinical Oncology. CSCO guidelines for diagnosis and treatment of hepatocellular carcinoma(2020)[M]. Beijing: China People's Health Press, 2020: 28-29. (in Chinese)

    中国临床肿瘤学会. 原发性肝癌诊疗指南2020[M]. 北京:中国人民卫生出版社, 2020: 28-29.
    [15]
    CALDERARO J, COUCHY G, IMBEAUD S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification[J]. J Hepatol, 2017, 67(4): 727-738. DOI: 10.1016/j.jhep.2017.05.014
    [16]
    NISHIDA N, KUDO M. Oncogenic signal and tumor microenvironment in hepatocellular carcinoma[J]. Oncology, 2017, 93(Suppl 1): 160-164.
    [17]
    DIBBLE CC, MANNING BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output[J]. Nat Cell Biol, 2013, 15(6): 555-564. DOI: 10.1038/ncb2763
    [18]
    HOWELL JJ, RICOULT SJ, BEN-SAHRA I, et al. A growing role for mTOR in promoting anabolic metabolism[J]. Biochem Soc Trans, 2013, 41(4): 906-912. DOI: 10.1042/BST20130041
    [19]
    European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16[J]. Cell, 1993, 75(7): 1305-1315. DOI: 10.1016/0092-8674(93)90618-Z
    [20]
    CRINO PB, NATHANSON KL, HENSKE EP. The tuberous sclerosis complex[J]. N Engl J Med, 2006, 355(13): 1345-1356. DOI: 10.1056/NEJMra055323
    [21]
    NABBOUT R, BELOUSOVA E, BENEDIK MP, et al. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study[J]. Epilepsia Open, 2019, 4(1): 73-84. DOI: 10.1002/epi4.12286
    [22]
    JANSEN AC, BELOUSOVA E, BENEDIK MP, et al. Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex[J]. Front Neurol, 2019, 10: 705. DOI: 10.3389/fneur.2019.00705
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (722) PDF downloads(37) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return